Benchmark reissued their speculative buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH – Free Report) in a research note published on Tuesday morning, Benzinga reports. Benchmark currently has a $17.00 price objective on the stock. Separately, HC Wainwright reissued a buy rating and set a $20.00 price objective on shares of Reviva Pharmaceuticals in a […]
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024 biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
In an interview, Larry Ereshefsky, PharmD, discussed other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism.
Reviva Pharma s Novel Funding Approach In Schizophrenia lifescienceleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lifescienceleader.com Daily Mail and Mail on Sunday newspapers.